Rockefeller Capital Management’s Aclaris Therapeutics ACRS Stock Holding History
Bought
Maintained
Sold
Other funds holding ACRS
BCM
Rockefeller Capital Management's ACRS Position: Q3 2026 in Review
Rockefeller Capital Management held its Aclaris Therapeutics (ACRS) position steady in Q3 2026 at 6,112 shares worth $32.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3676.
Rockefeller Capital Management first reported a position in ACRS in Q1 2020 and has held it in 5 quarters since. The position peaked at $32.3K in Q2 2026. 166 funds tracked by Wall St. Rank hold ACRS as of Q3 2026.
- Rockefeller Capital Management held 6,112 shares of Aclaris Therapeutics worth $32.1K as of Q3 2026.
- Rockefeller Capital Management left its Aclaris Therapeutics share count unchanged in Q3 2026.
- Aclaris Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q3 2026, its #3676 holding.
- Rockefeller Capital Management first reported a position in Aclaris Therapeutics in Q1 2020 and has held it in 5 quarters since.
- Rockefeller Capital Management's Aclaris Therapeutics position peaked at $32.3K in Q2 2026.
- 166 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2026.
Based on Rockefeller Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.